Dimeric Smac mimetics/IAP inhibitors as in vivo-active pro-apoptotic agents. Part II: Structural and biological characterization

Bioorg Med Chem. 2012 Nov 15;20(22):6709-23. doi: 10.1016/j.bmc.2012.09.041. Epub 2012 Sep 24.

Abstract

Novel pro-apoptotic, homodimeric and heterodimeric Smac mimetics/IAPs inhibitors connected through head-head (8), tail-tail (9) or head-tail linkers (10), were biologically and structurally characterized. In vitro characterization (binding to BIR3 and linker-BIR2-BIR3 domains from XIAP and cIAP1, cytotoxicity assays) identified early leads from each dimer family. Computational models and structural studies (crystallography, NMR, gel filtration) partially rationalized the observed properties for each dimer class. Tail-tail dimer 9a was shown to be active in a breast and in an ovary tumor model, highlighting the potential of dimeric Smac mimetics/IAP inhibitors based on the N-AVPI-like 4-substituted 1-aza-2-oxobicyclo[5.3.0]decane scaffold as potential antineoplastic agents.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Animals
  • Binding Sites
  • Biomimetic Materials / chemistry*
  • Biomimetic Materials / therapeutic use
  • Biomimetic Materials / toxicity
  • Cell Line, Tumor
  • Cell Survival / drug effects
  • Crystallography, X-Ray
  • Dimerization
  • Female
  • HL-60 Cells
  • Half-Life
  • Humans
  • Inhibitor of Apoptosis Proteins / antagonists & inhibitors*
  • Inhibitor of Apoptosis Proteins / metabolism
  • Mice
  • Mice, Nude
  • Molecular Dynamics Simulation
  • Nuclear Magnetic Resonance, Biomolecular
  • Oligopeptides / chemistry*
  • Ovarian Neoplasms / drug therapy
  • Protein Structure, Tertiary
  • Structure-Activity Relationship
  • Transplantation, Heterologous

Substances

  • Inhibitor of Apoptosis Proteins
  • Oligopeptides
  • SMAC peptide